Earnings
Home›Earnings›Analyst Ratings›Angel One stays bullish on Lincoln Pharmaceuticals wit…
Angel One stays bullish on Lincoln Pharmaceuticals with 39% upside target
The brokerage’s view is supported by Lincoln Pharmaceuticals’ Q1 FY27 results, including a 30.9% year over year rise in consolidated net profit to ₹36 crore.
Lincoln Pharmaceuticals Ltd, an Ahmedabad-based branded-generic company, has seen its shares trade under profit booking after hitting a 52-week high of ₹770 apiece on the NSE in late May 2026, according to LiveMint Markets.
Despite the pullback from the May peak, Angel One has reiterated a buy call on the stock with a 12-month target of ₹845 per share, implying about 39% upside versus a reported share price of ₹608.
Angel One pointed to Lincoln’s diversified portfolio, spanning 600-plus formulations across 15-plus therapeutic areas, with a domestic presence across segments including cardiac, diabetic, dermatology, gynaecology, ENT and anti-infectives, and exports across 60-plus countries.
In its assessment, the brokerage cited Q1 FY27 performance, saying consolidated net profit rose 30.9% year over year to ₹36 crore while total income grew 19% to ₹202 crore, and EBITDA increased 32% to ₹52 crore. It also highlighted core operating profit up about 15% year over year on roughly 15% revenue growth, with operating margins near 15.5%, plus a management target of ₹1,000 crore revenue within three years.